Epitalon is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-20. Numbers and descriptions here follow the published literature rather than marketing material.
In its supplied form epitalon is a white to off-white powder, usually lyophilized and often hygroscopic. It dissolves readily in water and in aqueous buffers, and it is commonly handled as the acetate or trifluoroacetate salt to improve stability during purification and drying. The amide backbone is labile in aqueous media, so solutions are less durable than the dry solid. Handling notes in the chemical literature therefore emphasize keeping the powder dry, cool and shielded from light until it is dissolved.
Epitalon is a synthetic tetrapeptide whose sequence is alanine-glutamate-aspartate-glycine, written in single-letter code as AEDG. The four residues are joined by three peptide bonds, giving a linear backbone with no branching and no disulfide bridges. Its calculated molecular mass for the free form is approximately 390.3 daltons, a figure that rises when the compound is supplied as an acetate or trifluoroacetate salt. Because the chain is short, the molecule is defined entirely by its residue order rather than by any folded three-dimensional structure.
Storage recommendations center on limiting moisture, heat, and light. The dry powder is generally kept at minus 20 degrees Celsius, and some suppliers recommend minus 80 degrees for long-term archival. Once dissolved, solutions are usually aliquoted and frozen to avoid repeated freeze-thaw cycles, which can promote aggregation or degradation. Aqueous stability depends on pH and concentration, and buffered saline is often preferred over plain water for biological work. Stability data specific to epitalon remain limited, so general peptide-handling practices are applied by analogy rather than from product-specific validation.
Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and its calculated monoisotopic mass is approximately 390.35 daltons. The compound does not occur naturally as a free peptide; it is produced by solid-phase peptide synthesis. Because it contains two acidic residues and no basic residues, the neutral form carries a net negative charge at physiological pH. This charge profile influences how the peptide behaves in solution and during chromatographic analysis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic tetrapeptide | Four residues, linear chain |
| Residue sequence | Ala-Glu-Asp-Gly | Single-letter form AEDG |
| Calculated mass | 390.3 daltons | Value for the free, uncharged form |
| Appearance | White to off-white powder | Usually supplied lyophilized |
| Solubility | Freely soluble in water | Often handled as a salt form |
The compound is generally presented as a synthetic fragment of epithalamin, a pineal gland extract investigated in the former Soviet Union from the 1970s onward. Vladimir Khavinson and colleagues in Saint Petersburg developed short peptides modelled on such extracts, and epitalon became the most widely cited of those sequences. Most primary reports appeared in Russian-language journals or in proceedings with limited international circulation. Independent replication in laboratories outside that network remains sparse, and much repeated secondary material traces back to a small number of originating groups.
Laboratory work has examined effects on telomerase activity in cultured cells, on melatonin rhythms in animals, and on markers of oxidative stress. Some experiments report measurable changes while others show none, and the reported findings rest largely on small studies. The absence of large independent trials means the generality of these results is unresolved rather than settled. Review articles occasionally apply the label geroprotector, a term that reflects a research hypothesis about ageing rather than an established clinical finding.
Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.
Material supplied for laboratory use is normally a lyophilised white to off-white powder that dissolves readily in water and in isotonic saline. Lyophilised cakes are hygroscopic and should be equilibrated to room temperature before opening to limit condensation on the solid. Solutions are typically prepared at milligram-per-millilitre concentrations and divided into single-use aliquots, because repeated freeze–thaw cycles degrade short peptides. Aqueous solutions are far less stable than the dry powder, and identity is usually verified by mass spectrometry alongside purity estimation from reversed-phase high-performance liquid chromatography.
Epitalon is a synthetic linear tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and the calculated mass is approximately 390.35 g/mol. The compound is made by solid-phase peptide synthesis rather than extracted from tissue, although early work described it as a short fragment of a peptide fraction obtained from bovine pineal extract. In the research literature the spelling epitalon and the variant epithalone both appear, while AEDG is the standard code used in peptide nomenclature.
Most experimental work has been carried out in cell culture and animal models. Several reports describe changes in telomerase activity and proliferation in cultured cells, while rodent studies have examined lifespan, melatonin rhythm and reproductive endpoints. Human data remain limited, and much of the published clinical material consists of small trials with incomplete reporting of methods and controls. Whether the cell and animal findings translate into measurable effects in people is an open question, and the mechanistic basis of the reported telomerase changes is not fully established.
Discussions in the literature often conflate three distinct entities: the pineal extract epithalamin, the isolated tetrapeptide AEDG, and commercial preparations sold under similar names. Reviews citing older Russian-language studies sometimes omit detail on purity, route of administration and control groups, which makes cross-study comparison difficult. Researchers working with the compound generally note the need for independent replication, standardized enzyme assays, and clearer reporting of peptide identity. These caveats are relevant when weighing claims that appear in secondary sources rather than in primary reports.
The published literature is dominated by a small number of research groups, much of it in Russian-language journals, and independent replication outside those groups is limited. Studies are typically small, use cultured cells or rodent models, and report endpoints that differ between papers, which makes comparison difficult. Large randomised human trials have not appeared in the indexed literature. Questions about absorption, distribution and clearance are therefore still treated as open in reviews that mention the compound.
Epitalon is a synthetic tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. Its design traces to epithalamin, a peptide fraction prepared from bovine pineal gland extracts that researchers in Saint Petersburg began investigating in the 1970s. The compound has a molecular formula of C14H22N4O9 and a nominal molecular mass near 390 daltons. It holds no approved drug status in the United States or the European Union, and material sold under this name is generally offered as a research chemical rather than a finished pharmaceutical product.
Producer Steve Lillywhite, who had gained fame with successful productions of Simple Minds and U2, was to produce Grace Under Pressure. He backed out at the last moment, however, much to the ire of Lee, Lifeson and Peart. Lee said, "Steve Lillywhite is really not a man of his word ... after agreeing to do our record, he got an offer from Simple Minds, changed his mind, blew us off ... so it put us in a horrible position." Rush eventually hired Peter Henderson to co-produce and engineer the album instead.
252.01 Hyperparathyroidism, primary 252.1 Hypoparathyroidism 253 Disorders of the pituitary gland and its hypothalamic control 253.3 Growth hormone deficiency 253.6 SIADH 254 Diseases of thymus gland 255 Disorders of adrenal glands 255.0 Cushing's syndrome 256 Ovarian dysfunction 256.2 Ovarian failure, postablative 256.39 Ovarian failure, other 256.4 Ovaries, polycystic 257 Testicular dysfunction 257.2 Testicular hypofunction 258 Polyglandular dysfunction and related disorders 259 Other endocrine disorders 259.0 Puberty, delayed 259.1 Sexual precocity
Tobacco harm reduction describes actions taken to lower the health risks associated with using tobacco, especially combustible forms, without abstaining completely from tobacco and nicotine. Some of these measures include switching to safer (lower tar) cigarettes, switching to snus or dipping tobacco, or using a non-tobacco nicotine delivery systems. In recent years, the growing use of electronic cigarettes (or vaping) for smoking cessation, whose long-term safety remains uncertain, has sparked an ongoing controversy among medical and public health between those who seek to restrict and discourage all use until more is known and those who see them as a useful approach for harm reduction, whose risks are most unlikely to equal those of smoking tobacco. "Their usefulness in tobacco harm reduction as a substitute for tobacco products is unclear", but in an effort to decrease tobacco related death and disease, they have a potential to be part of the strategy.
=== Human use === Nitrofurazone was previously available as a prescription in the U.S., and was indicated as a topical solution, topical cream, or topical ointment for the treatment of bacterial skin infections, wounds, burns, and ulcers. It was also used as a prophylactic measure to prevent infection that could potentially result in skin graft rejection. Nitrofurazone is still very popular as a topical solution for the treatment of tonsillitis in Russia.
Neutrons produced by fission of 238U have lower energies than the original neutron (they behave as in an inelastic scattering), usually below 1 MeV (i.e., a speed of about 14,000 km/s), the fission threshold to cause subsequent fission of 238U, so fission of 238U does not sustain a nuclear chain reaction. Fast fission of 238U in the secondary stage of a thermonuclear weapon, due to the production of high-energy neutrons from nuclear fusion, contributes greatly to the yield and to fallout of such weapons. Fast fission of 238U tampers has also been evident in pure fission weapons. The fast fission of 238U also makes a significant contribution to the power output of some fast-neutron reactors.
Sources: en.wikipedia.org
Fatty acid esters of estradiol, such as estradiol benzoate, estradiol valerate, and estradiol cypionate, have been found to have similar estrogenic potency to estradiol but a comparatively longer duration with transdermal administration in animal studies. Regardless of administration form, such as patch or gel, transdermal estradiol is transported into the skin, including through the stratum corneum, epidermis, and dermis, by a passive diffusion process. Following this, estradiol is then taken up by local capillary blood vessels and delivered into the circulation. There is a depot effect in the skin with transdermal estradiol, which results in continuous delivery of transdermal estradiol into the circulation. This is because the skin functions as a semipermeable membrane and there is a concentration gradient between the application site of transdermal estradiol and capillary blood, with the rate of diffusion of estradiol across the stratum corneum being the specific rate-limiting factor in absorption. As a result, peaks and troughs in circulating estradiol levels are limited, and the skin and subcutaneous fat act as a reservoir of estradiol that maintains circulating estradiol levels between doses. For these reasons, transdermal estradiol can provide near-constant circulating levels of estradiol, similarly to oral estradiol. Enzymes that metabolize estradiol are minimally expressed in the skin, and for this reason, the metabolism of estradiol in the skin is low. The site of application of transdermal estradiol can influence its bioavailability.
== Bibliography == Claret, Jaume; Santirso, Manuel (2014). La construcción del catalanismo. Historia de un afán político (in Spanish). Madrid: Los Libros de la Catarata. ISBN 978-84-8319-898-8. García de Cortázar, Fernando; González Vesga, José Manuel (2012). Breve historia de España (in Spanish) (6º ed.). Madrid: Alianza Editorial. ISBN 978-84-206-7374-5. Juliá, Santos (1999). Un siglo de España. Política y sociedad (in Spanish). Madrid: Marcial Pons. ISBN 84-9537903-1. Powell, Charles (2002) [2001]. España en democracia, 1975-2000 (in Spanish). Barcelona: Plaza & Janés. ISBN 84-9759-022-8. Preston, Paul (2003). Juan Carlos. El rey de un pueblo (in Spanish). Barcelona: Plaza & Janés. ISBN 84-01-37824-9. Ruiz, David (2002). La España democrática (1975-2000). Política y sociedad (in Spanish). Madrid: Síntesis. ISBN 84-9756-015-9. Sánchez-Cuenca, Ignacio (2012). Años de cambios, años de crisis. Ocho años de gobiernos socialistas, 2004-2011 (in Spanish). Madrid: Los Libros de la Catarata-Fundación Alternativas. ISBN 978-84-8319-682-3. Sánchez-Cuenca, Ignacio (2014). La impotencia democrática. Sobre la crisis política de España (in Spanish). Madrid: Los Libros de la Catarata. ISBN 978-84-8319-881-0. Tusell, Javier (1997). La transición española. La recuperación de las libertades (in Spanish). Madrid: Historia 16-Temas de Hoy. ISBN 84-7679-327-8.
== History == The history of light therapy can be traced back to ancient Egypt and India, where therapy with natural sunlight was first used to treat leucoderma. In the 1850s, Florence Nightingale's advocacy of exposure to clean air and sunlight for health restoration also contributed to the initial development of light therapy for treatments. Later, Downes and Blunt's experiment in 1877 suggested sunlight's effect on fungal growth inhibition, which further evidenced the efficiency of light therapy . The modern use of light therapy with artificial lights started in the late 19th century. The Danish Nobel Prize winner in medicine and physiology, Niels Finsen, pioneered the use of light as a therapy for skin tuberculosis (lupus vulgaris). His creation of the light device "Finsen lamp" as a lupus vulgaris treatment marked the beginning of modern light therapy. The application of LED lights in cosmetology became more popular in the 1980s, particularly for acne recovery, due to its ability of collagen production. Since the early 2000s, the use of LED light therapy in the medical field has become more versatile, including treatment for skin conditions, chronic diseases, and the realignment of human circadian rhythm. It has now become a commonly used therapy in both the beauty and medical fields.
== Invertebrates == It is less common to find examples of dedifferentiation (due to a lack of regenerative ability) in most invertebrates. This brief example outlines dedifferentiation in an invertebrate species, and interestingly involves the Msx pathway, as detailed above in the mechanisms section.
Sources: en.wikipedia.org
The peptide contains four residues in the order alanine, glutamate, aspartate and glycine, abbreviated AEDG. The chain is linear and held together by three peptide bonds. Its calculated mass for the uncharged free form is about 390.3 daltons.
Epithalamin refers to a crude preparation derived from bovine pineal tissue, which contains many components. Epitalon is a single synthetic tetrapeptide identified from that material and produced by chemical synthesis. The two names are sometimes confused because early reports treated the synthetic peptide as an active fragment of the extract.
It has been registered for clinical use in Russia, where it is associated with a small family of short peptides. In most other jurisdictions it is not an approved medicine and is traded as a research chemical. Regulatory status varies by country and changes over time.
Epitalon is a synthetic tetrapeptide built from four amino acids: alanine, glutamate, aspartate, and glycine. It is not extracted from a natural source but made in the laboratory by chemical synthesis. Its short length makes it relatively straightforward to produce at high purity.